Short Bowel Syndrome (SBS)
Conditions
Brief summary
The main aim of this study is to assess the effectiveness and side effects of teduglutide (Revestive®) in real-world clinical practice setting in adult participants with intestinal failure due to short bowel syndrome (SBS-IF) in Canada. This study is about collecting existing data only; participants receive teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. No new information will be collected during this study. The study will be conducted using data from the Takeda OnePath Patient Support Program (PSP) or Takeda Global Pharmacovigilance.
Interventions
OTHERNon-interventional Study
This is non-interventional study.
Sponsors
Takeda
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants more than or equal to (\>=) 18 years of age at first dose of teduglutide diagnosed with intestinal failure due to short bowel syndrome as a result of intestinal resection. Note: As SBS as result of major intestinal resection is a criterion for teduglutide treatment reimbursement, it is assumed that all participants receiving teduglutide in the PSP have SBS-IF as a result of intestinal resection. * Stable participants with SBS-IF who were dependent on parenteral support prior to teduglutide treatment initiation, and were treated with teduglutide during the study period with at least 6 months of follow-up data available before the end of the study period. * Participants who have provided informed consent for secondary use of data for research.
Exclusion criteria
\- Participants with active gastrointestinal malignancy OR a history of gastrointestinal malignancy in the past 5 years before start of treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Weekly Volume of Parenteral Nutrition (PN)/Intravenous (IV) Fluid Requirement at Week 24 | Baseline and at Week 24 | Weekly volume of PN/IV fluid requirement at baseline before teduglutide treatment and at Week 24 after initiation of teduglutide treatment will be reported. |
| Average Change in Number of Days per Week With PN/IV Usage | 6 months before teduglutide treatment initiation and 6 months after teduglutide treatment initiation (approximately 12 months | Average change in number of days per week with PN/IV usage in the 6 months before teduglutide treatment initiation and 6 months after teduglutide treatment initiation will be reported. |
| Percentage of Participants Achieving PN/IV Independence During the Study Period | Up to 48 Months | Percentage of participants who will achieve PN/IV independence during the study period will be reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Number of Days per Week With PN/IV Usage | Baseline and at 6, 12, 24, 36 and 48 months after initiation of teduglutide treatment | Change from baseline in number of days per week with PN/IV usage at 6,12, 24, 36 and 48 months after teduglutide treatment initiation will be reported. |
| Change From Baseline in Weekly Volume of PN/IV Fluid Requirement | Baseline and at 6, 12, 24, 36 and 48 months after initiation of teduglutide treatment | Change from baseline in weekly volume of PN/IV fluid requirement at 6,12, 24, 36 and 48 months after initiation of treatment with teduglutide will be reported. |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | From treatment initiation up to 6 months after teduglutide treatment discontinuation (approximately 48 months) | An AE is any untoward medical occurrence in a participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. A SAE is any untoward clinical manifestation of signs, symptoms or outcomes (whether considered related to investigational product or not and at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, congenital abnormality/birth defect, an important medical event. |
| Number of Participants With Reasons of Treatment Interruption and Discontinuation | From teduglutide treatment initiation up to 48 months | Number of participants with reasons of treatment interruption and discontinuation will be reported. |
| Number of Participants Achieving Response of 20 percent (%) to 100% Reduction From Baseline in Weekly Parenteral Support (PS) Volume | Up to 48 months after teduglutide treatment initiation | Number of participants achieving response of 20% to 100% reduction from baseline in weekly PS volume will be reported. |
| Percentage of Participants Achieving 20 % to 100% Reduction From Baseline in Weekly Parenteral Support (PS) Volume | Baseline and at 6, 12, 24, 36 and 48 months after initiation of teduglutide treatment | Percentage of participants achieving 20% to 100% reduction from baseline in weekly PS volume at 6, 12, 24, 36 and 48 months after initiation of treatment with teduglutide will be reported. |
Countries
Canada
Outcome results
None listed